Your browser doesn't support javascript.
loading
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
Nickols, Nicholas G; Nazarian, Ramin; Zhao, Shuang G; Tan, Victor; Uzunangelov, Vladislav; Xia, Zheng; Baertsch, Robert; Neeman, Elad; Gao, Allen C; Thomas, George V; Howard, Lauren; De Hoedt, Amanda M; Stuart, Josh; Goldstein, Theodore; Chi, Kim; Gleave, Martin E; Graff, Julie N; Beer, Tomasz M; Drake, Justin M; Evans, Christopher P; Aggarwal, Rahul; Foye, Adam; Feng, Felix Y; Small, Eric J; Aronson, William J; Freedland, Stephen J; Witte, Owen N; Huang, Jiaoti; Alumkal, Joshi J; Reiter, Robert E; Rettig, Matthew B.
Afiliação
  • Nickols NG; Department of Radiation Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, 90073, USA.
  • Nazarian R; Department of Radiation Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 90095, USA.
  • Zhao SG; Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 90095, USA.
  • Tan V; Division of Dermatology/Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 90095, USA.
  • Uzunangelov V; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA.
  • Xia Z; Department of Medicine, Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, Piscatway, NJ, 08854, USA.
  • Baertsch R; Center for Biomolecular Science and Engineering, Jack Baskin School of Engineering, University of California, Santa Cruz, Santa Cruz, CA, 95064, USA.
  • Neeman E; Department of Molecular Microbiology & Immunology, Computational Biology Program, Oregon Health and Science University, Portland, OR, 97239, USA.
  • Gao AC; Center for Biomolecular Science and Engineering, Jack Baskin School of Engineering, University of California, Santa Cruz, Santa Cruz, CA, 95064, USA.
  • Thomas GV; Division of Hematology-Oncology/Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 90095, USA.
  • Howard L; Department of Urology, School of Medicine, University of California Davis, Sacramento, CA, 95817, USA.
  • De Hoedt AM; Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, OR, 97239, USA.
  • Stuart J; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, 27710, USA.
  • Goldstein T; Division of Urology, Durham Veterans Affairs Medical Center, Durham, NC, 27705, USA.
  • Chi K; Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA, 95064, USA.
  • Gleave ME; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
  • Graff JN; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  • Beer TM; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  • Drake JM; VA Portland Health Care System, Portland and Knight Cancer Institute, Oregon Health and Science University, Portland, OR, 97239, USA.
  • Evans CP; Department of Medicine, Oregon Health and Science University, Portland, OR, 97239, USA.
  • Aggarwal R; Department of Medicine, Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, Piscatway, NJ, 08854, USA.
  • Foye A; Department of Urology, School of Medicine, University of California Davis, Sacramento, CA, 95817, USA.
  • Feng FY; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
  • Small EJ; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
  • Aronson WJ; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA.
  • Freedland SJ; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, 94143, USA.
  • Witte ON; Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 90095, USA.
  • Huang J; Division of Urology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, 90073, USA.
  • Alumkal JJ; Division of Urology, Durham Veterans Affairs Medical Center, Durham, NC, 27705, USA.
  • Reiter RE; Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • Rettig MB; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 90095, USA.
Prostate Cancer Prostatic Dis ; 22(4): 531-538, 2019 12.
Article em En | MEDLINE | ID: mdl-30804427

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema de Sinalização das MAP Quinases / Proteína Quinase 3 Ativada por Mitógeno / Inibidores de Proteínas Quinases / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Assunto da revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema de Sinalização das MAP Quinases / Proteína Quinase 3 Ativada por Mitógeno / Inibidores de Proteínas Quinases / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Assunto da revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido